EBC-129 demonstrates early activity and manageable safety in patients with heavily pretreated pancreatic cancer, supporting ...

The addition of relacorilant to nab-paclitaxel significantly extended survival for women with platinum-resistant ovarian ...

Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of accepted research at key scientific conferences this spring, ...

The data may change how patients are treated following a diagnosis for advanced triple-negative breast cancer, one expert ...

Abbreviations: AB, antibiotic prophylaxis; DOC, docetaxel; ECOG PS, Eastern Cooperative Oncology Group performance score; FEC-D, fluorouracil, epirubicin ...

Trodelvy, in combination with Keytruda, significantly lowers the risk of progression in triple-negative breast cancer by 35%, ...

The Company previously reported exploratory biomarker data from the SER-155 Phase 1b study showing evidence of improved intestinal epithelial barrier integrity and modulation of systemic inflammatory ...